Article
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
The Lancet. Oncology - 1 Dec 2016
Goss Glenwood, Tsai Chun-Ming, Shepherd Frances A, Bazhenova Lyudmila, Lee Jong Seok, Chang Gee-Chen, Crino Lucio, Satouchi Miyako, Chu Quincy, Hida Toyoaki, Han Ji-Youn, Juan Oscar, Dunphy Frank, Nishio Makoto, Kang Jin-Hyoung, Majem Margarita, Mann Helen, Cantarini Mireille, Ghiorghiu Serban, Mitsudomi Tetsuya
Abstract excerpt
BACKGROUND: Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR Thr790Met resistance mutation. We assessed the efficacy and safety of osimertinib in patients with EGFR Thr790Met-positive non-small-cell lung cancer (NSCLC), who had progressed after previous therapy with an approved EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.